Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: A chart review analysis

Current Medical Research and Opinion

Volumn 28, Issue 11, 2012, Pages 1831-1839

  Chen, Lei ^a   Guérin, Annie ^b   Xie, Jipan ^b   Wu, Eric Q ^b   Yu, Andrew P ^b   Ericson, Solveig G ^a   Jabbour, Elias ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ANALYSIS GROUP   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myeloid leukemia; Imatinib; Monitoring; Tyrosine kinase inhibitors

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; COMMUNITY CARE; CYTOGENETICS; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PATIENT MONITORING; PRACTICE GUIDELINE; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICAL AUDIT; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84868705243     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.741577     Document Type: Review

References (20)

1. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
2. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI57I (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:abstr 1126
3. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9
4. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-6
5. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
6. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
7. Hanfstein B, Müller MC, Hehlmann R et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 Sep;26(9):2096-102
8. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758-65
9. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Treatment optimization by high-dose imatinib: randomized comparison of imatinib 800 mg versus imatinib 400 mg\+/-IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: the German CML-study IV. J Clin Oncol 2010;28:abstr 6517
10. Press RD, Love Z, Tronnes AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006;107:4250-6
11. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007;13:6136-43
12. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesy-late. Clin Cancer Res 2005;11:3425-32
13. Hochhaus A, Saglio G, Chuah C et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels d R% at 3 months are associated with improved responses in patients with newly diagnosed CML-CP: analysis of molecular response kinetics in the DASISION trial. Poster presented at the 53rd ASH Meeting and Exposition, 10-13 December 2011, San Diego, CA, USA
14. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232-8
15. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007;110:2828-37
16. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia [v1.2013], 2012
17. European LeukemiaNet. Recommendations from the European LeukemiaNet for the Management of Chronic Myeloid Leukemia (CML) [2010 Update], 2009
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia [v2.2009], 2008
19. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20
20. Michallet M, Tulliez M, Corm S, et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin 2010;26:307-17